Search

Your search keyword '"Dansin E"' showing total 382 results
Start Over Author "Dansin E"
382 results on '"Dansin E"'

2. Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.

Author

Baudin, E., Capdevila, J., Hörsch, D., Singh, S., Caplin, M. E., Wolin, E. M., Buikhuisen, W., Raderer, M., Dansin, E., Grohe, C., Ferone, D., Houchard, A., Truong-Thanh, X-M., and Reidy-Lagunes, D.

Subjects
HARPSICHORD, SOMATOSTATIN receptors, NEUROENDOCRINE tumors, PLACEBOS, PROGRESSION-free survival
Abstract

Prospective data are lacking on early somatostatin analog (SSA) therapy in bronchopulmonary neuroendocrine tumors (BP-NETs; typical carcinoids and atypical carcinoids (TCs and ACs)). SPINET (EudraCT: 2015-004992-62; NCT02683941) was a phase III, double-blind study of lanreotide autogel/depot (LAN; 120 mg every 28 days) plus best supportive care (BSC) vs placebo plus BSC, with an optional open-label treatment phase (LAN plus BSC). Patients had metastatic/unresectable, somatostatin receptor (SSTR)-positive TCs or ACs. Recruitment was stopped early owing to slow accrual; eligible patients from the double-blind phase transitioned to open-label LAN. The adapted primary endpoint was progression-free survival (PFS) during either phase for patients receiving LAN. Seventy-seven patients were randomized (LAN, n = 51 (TCs, n = 29; ACs, n = 22); placebo, n = 26 (TCs, n = 16; ACs, n = 10)). Median (95% CI) PFS during double-blind and open-label phases in patients receiving LAN was 16.6 (11.3; 21.9) months overall (primary endpoint), 21.9 (12.8, not calculable (NC)) months in TCs, and 13.8 (5.4; 16.6) months in ACs. During double-blind treatment, median (95% CI) PFS was 16.6 (11.3; 21.9) months for LAN vs 13.6 (8.3; NC) months for placebo (not significant); corresponding values were 21.9 (13.8; NC) and 13.9 (13.4; NC) months, respectively, in TCs and 13.8 (5.4; 16.6) and 11.0 (2.8; 16.9) months, respectively, in ACs. Patients’ quality of life did not deteriorate and LAN was well tolerated. Although recruitment stopped early and the predefined sample size was not met, SPINET is the largest prospective study to date of SSA therapy in SSTR-positive TCs and ACs and suggests clinical benefit in TCs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. Carcinomes neuroendocrines à grandes cellules (CNEGC) : actualités 2024

Author

Gaye, E., Jannin, A., Do Cao, C., and Dansin, E.

Abstract

Les carcinomes neuro-endocrines à grandes cellules (CNEGC) sont des tumeurs rares de haut grade de malignité et de pronostic péjoratif. La prise en charge des CNEGC demeure complexe et certaines situations cliniques (induction, stades métastatïques…) font encore l’objet de nombreuses interrogations. Si l’impact du ciblage moléculaire de ces tumeurs sur le type de traitement systémique optimal à préconiser reste à démontrer, l’évaluation prospective de l’immunothérapie dans les stades métastatiques se met en place et pourrait ouvrir de nouvelles options thérapeutiques.

Published
2024
Full Text
View/download PDF

5. Efficacité et tolérance en vie réelle du sotorasib en comparaison au docétaxel dans le traitement des carcinomes bronchiques non à petites cellules métastatiques avec mutation KRASG12C

Author

Muchembled, M., primary, Gauvain, C., additional, Escande, F., additional, Tavernier, J.-Y., additional, Saelens, T., additional, Ampère, A., additional, Henni, A., additional, Chuffart, C., additional, Thirard, L., additional, Dansin, E., additional, Wasielewski, E., additional, Leroy, V., additional, and Cortot, A., additional

Published
2024
Full Text
View/download PDF

16. Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

Author

Moran, T., Wei, J., Cobo, M., Qian, X., Domine, M., Zou, Z., Bover, I., Wang, L., Provencio, M., Yu, L., Chaib, I., You, C., Massuti, B., Song, Y., Vergnenegre, A., Lu, H., Lopez-Vivanco, G., Hu, W., Robinet, G., Yan, J., Insa, A., Xu, X., Majem, M., Chen, X., de las Peñas, R., Karachaliou, N., Sala, M.A., Wu, Q., Isla, D., Zhou, Y., Baize, N., Zhang, F., Garde, J., Germonpre, P., Rauh, S., ALHusaini, H., Sanchez-Ronco, M., Drozdowskyj, A., Sanchez, J.J., Camps, C., Liu, B., Rosell, R., Colinet, B., De Grève, J., Germonpré, P., Chen, H., Du, J., Gao, Y., Hu, J., Kong, W., Li, L., Li, R., Li, X., Liu, J., Ren, W., Wen, L., Xiao, X., Yang, J., Yang, M., Yang, Y., Yin, J., Yue, X., Zhang, J., Zhu, L., Bombaron, P., Chouaid, C., Dansin, E., Fournel, P., Fraboulet, G., Gervais, R., Hominal, S., Kahlout, S., Lecaer, H., Lena, H., LeTreut, J., Locher, C., Molinier, O., Monnet, I., Oliviero, G., Schoot, R., Thomas, P., Vergnènegre, A., Berchem, G., Al Husaini, H., Aparisi, F., Arriola, E., Ballesteros, I., Barneto, I., Bernabé, R., Blasco, A., Bosch-Barrera, J., Calvo de Juan, V., Carcereny, E., Catot, S., De las Peñas, R., Dómine, M., Felip, E., García-Campelo, M.R., García-Girón, C., García-Gómez, R., Garcia-Sevila, R., Gasco, A., Gil, J., González-Larriba, J.L., Hernando-Polo, S., Jantus, E., Jiménez, B., Lianes, P., López-López, R., López-Martín, A., López-Vivanco, G., Macias, J.A., Marti-Ciriquian, J.L., Montoyo, R., Morales-Espinosa, D., Morán, T., Moreno, M.A., Pallares, C., Parera, M., Pérez-Carrión, R., Porta, R., Reguart, N., Rosillo, F., Sanchez, J.M., Sullivan, I., Terrasa, J., Trigo, J.M., Valdivia, J., Viñolas, N., Viteri, S., Botia-Castillo, M., Mate, J.L., Perez-Cano, M., Ramirez, J.L., Sanchez-Rodriguez, B., Taron, M., Tierno-Garcia, M., Mijangos, E., Ocaña, J., Pereira, E., Shao, J., Sun, X., and O'Brate, R.

Published
2014
Full Text
View/download PDF

17. 1629P Increased incidence of thymic epithelial tumors during COVID-19 pandemic: A retrospective analysis from the French RYTHMIC network

Author

Benitez, J.C., primary, Florez-Arango, J., additional, Boucher, M-E., additional, Dansin, E., additional, Kerjouan, M., additional, Bigay-Game, L., additional, Pichon, E., additional, Thillays, F., additional, Falcoz, P-E., additional, Lyubimova, S., additional, Oulkhouir, Y., additional, Calcagno, F., additional, Thiberville, L., additional, Clément-Duchêne, C., additional, Westeel, V., additional, Thomas, P.A., additional, Maury, J-M., additional, Molina, T., additional, Girard, N., additional, and Besse, B., additional

Published
2022
Full Text
View/download PDF

18. Pleural Mesothelioma

Author

Dansin, E., Dewas, S., Porte, H., Belkacémi, Yazid, editor, Mirimanoff, René-Olivier, editor, and Ozsahin, Mahmut, editor

Published
2010
Full Text
View/download PDF

19. LBA83 PECATI: A phase II trial to evaluate the efficacy and safety of lenvatinib in combination with pembrolizumab in pretreated advanced B3-thymoma and thymic carcinoma

Author

Remon Masip, J., Bironzo, P., Girard, N., Bigay-Game, L., Juan Vidal, O.J., de Castro Carpeño, J., Reguart Aransay, N., Greillier, L., Cousin, S., Dansin, E., Majem, M., Bernabe Caro, R., Mosquera Martinez, J., Diaz, M., Meya, A., Alcalá-López, D., Sanz, A.G., Righi, L., Novello, S., and Besse, B.

Published
2024
Full Text
View/download PDF

27. MA04.01 Multimodality Treatment and Outcome in Stage III Thymic Epithelial Tumors (TETs): A Retrospective Analysis From the French RYTHMIC Network

Author

Benítez, J.C., primary, Bluthgen, M.V., additional, Boucher, M., additional, Dansin, E., additional, Kerjouan, M., additional, Bigay-Game, L., additional, Pichon, E., additional, Thillays, F., additional, Falcoz, P., additional, Lyubimova, S., additional, Oulkhouir, Y., additional, Calcagno, F., additional, Thiberville, L., additional, Clément-Duchêne, C., additional, Weestel, V., additional, Missy, P., additional, Thomas, P., additional, Maury, J., additional, Molina, T., additional, Girard, N., additional, and Besse, B., additional

Published
2021
Full Text
View/download PDF

28. 1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib

Author

Descourt, R., primary, Pérol, M., additional, Rousseau-Bussac, G., additional, Planchard, D., additional, Mennecier, B., additional, Wislez, M., additional, Cadranel, J., additional, Cortot, A.B., additional, Guisier, F., additional, Galland, L., additional, Do, P., additional, Schott, R., additional, Dansin, E., additional, Arrondeau, J., additional, Auliac, J.B., additional, and Chouaid, C., additional

Published
2021
Full Text
View/download PDF

29. 1742TiP RADIORYTHMIC: Phase III, opened, randomized study of post-operative radiotherapy (PORT) versus surveillance in stage IIb/III of Masaoka Koga thymoma after complete surgical resection

Author

Basse, C., primary, Botticella, A., additional, Molina, T., additional, Falcoz, P-E., additional, Oulkhouir, Y., additional, Kerjouan, M., additional, Pichon, E., additional, Calcagno, F., additional, Thiberville, L., additional, Quantin, X., additional, Clément-Duchêne, C., additional, Khalifa, J., additional, Mazieres, J., additional, Le Tinier, F., additional, Dansin, E., additional, Thillays, F., additional, Besse, B., additional, Thomas, P-A., additional, Le Pechoux, C., additional, and Girard, N., additional

Published
2021
Full Text
View/download PDF

30. 1170O An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)

Author

Le Pechoux, C., primary, Barlesi, F., additional, Pourel, N., additional, Faivre-Finn, C., additional, Lerouge, D., additional, Zalcman, G., additional, Antoni, D., additional, Lamezec, B., additional, Nestle, U., additional, Boisselier, P., additional, Thillays, F., additional, Paumier, A., additional, Dansin, E., additional, Peignaux, K., additional, Madelaine, J., additional, Pichon, E., additional, Larrouy, A., additional, Riesterer, O., additional, Lavolle, A., additional, and Bardet, A., additional

Published
2021
Full Text
View/download PDF

31. 1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C

Author

Dziadziuszko, R., primary, Peters, S., additional, Gadgeel, S.M., additional, Mathisen, M.S., additional, Shagan, S.M., additional, Felip, E., additional, Morabito, A., additional, Cheema, P., additional, Dols, M. Cobo, additional, Andric, Z., additional, Barrios, C.H., additional, Yamaguchi, M., additional, Dansin, E., additional, Danchaivijitr, P., additional, Johnson, M., additional, Novello, S., additional, Gandara, D.R., additional, Schleifman, E., additional, Wang, J., additional, and Mok, T.S.K., additional

Published
2021
Full Text
View/download PDF

32. 1096O Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study

Author

Baudin, E., primary, Horsch, D., additional, Singh, S., additional, Caplin, M.E., additional, Ferone, D., additional, Wolin, E.M., additional, Capdevila, J., additional, Buikhuisen, W.A., additional, Raderer, M., additional, Dansin, E., additional, Grohe, C., additional, Houchard, A., additional, Truong Thanh, X-M., additional, and Reidy-Lagunes, D., additional

Published
2021
Full Text
View/download PDF

37. 47P Central nervous-system (CNS) metastases in thymic epithelial tumours (TET): Real-world insight from RYTHMIC

Author

Benitez, J.C., primary, Boucher, M-E., additional, Dansin, E., additional, Kerjouan, M., additional, Bigay-Game, L., additional, Pichon, E., additional, Thillays, F., additional, Falcoz, P., additional, Lyubimova, S., additional, Oulkhouir, Y., additional, Calcagno, F., additional, Thiberville, L., additional, Clément-Duchêne, C., additional, Westeel, V., additional, Missy, P., additional, Thomas, P.A., additional, Molina, T., additional, Girard, N., additional, and Besse, B., additional

Published
2021
Full Text
View/download PDF

38. FP05.04 Outcomes of Resected Thymic Epithelial Tumors (TET), insights from RYTHMIC

Author

Benitez, J.C., primary, Boucher, M.E., additional, Dansin, E., additional, Kerjouan, M., additional, Bigay-Game, L., additional, Pichon, E., additional, Thillays, F., additional, Falcoz, P.E., additional, Lyubimova, S., additional, Oulkhouir, Y., additional, Calcagno, F., additional, Thiberville, L., additional, Clément-Duchêne, C., additional, Morin, F., additional, Missy, P., additional, Thomas, P.A., additional, Maury, J., additional, Molina, T., additional, Girard, N., additional, and Besse, B., additional

Published
2021
Full Text
View/download PDF

40. Un essai international randomisé, comparant la radiothérapie conformationnelle postopératoire (RPO) à l’absence de RPO, chez des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) complètement réséqué et avec envahissement ganglionnaire médiastinal N2. Première analyse de l’essai Lung ART (IFCT-0503, UK NCRI, SAKK)

Author

Le Péchoux, C., primary, Pourel, N., additional, Barlési, F., additional, Faivre-Finn, C., additional, Lerouge, D., additional, Zalcman, G., additional, Antoni, D., additional, Lamezec, B., additional, Nestle, U., additional, Boisselier, P., additional, Dansin, E., additional, Paumier, A., additional, Peignaux, K., additional, Thillays, F., additional, Madeleine, J., additional, Pichon, E., additional, Larrouy, A., additional, Riesterer, O., additional, Lavolé, A., additional, and Bardet, A., additional

Published
2021
Full Text
View/download PDF

41. Traitements de première ligne et prise en charge du cancer broncho-pulmonaire non à petites cellules avancé ou métastatique avec une mutation EGFR–Analyse de la base nationale de données de vie réelle du programme Épidémio-stratégie médico-économique

Author

Girard, N., primary, Filleron, T., additional, Pérol, M., additional, Chouaid, C., additional, Debieuvre, D., additional, Quantin, X., additional, Dayen, C., additional, Lena, H., additional, Schott, R., additional, Gervais, R., additional, Schneider, S., additional, Otto, J., additional, Dansin, E., additional, Dubray Longeras, P., additional, Kaderbhai, C., additional, Madroszyk, A., additional, Clément-Duchêne, C., additional, Pichon, E., additional, Planchard, D., additional, Lemoine, A., additional, Bizieux, A., additional, Baranzelli, A., additional, Cousin, S., additional, Couch, D., additional, Hominal, S., additional, Thureau, S., additional, Le Treut, J., additional, Robain, M., additional, Hiret, S., additional, Simon, G., additional, and Audigier-Vallette, C., additional

Published
2021
Full Text
View/download PDF

42. Programme épidémio-stratégie médicoéconomique : une base nationale de données de vie réelle pour mieux comprendre la prise en charge du cancer bronchopulmonaire en France

Author

Pérol, M., primary, Carton, M., additional, Debieuvre, D., additional, Quantin, X., additional, Girard, N., additional, Audigier-Vallette, C., additional, Lena, H., additional, Filleron, T., additional, Schott, R., additional, Gervais, R., additional, Hiret, S., additional, Otto, J., additional, Dansin, E., additional, Dubray Longeras, P., additional, Kaderbhai, C., additional, Madroszyk, A., additional, Clément-Duchêne, C., additional, Pichon, E., additional, Planchard, D., additional, Lemoine, A., additional, Thureau, S., additional, Baranzelli, A., additional, Cousin, S., additional, Schneider, S., additional, Bizieux, A., additional, Le Treut, J., additional, Hominal, S., additional, Dayen, C., additional, Simon, G., additional, Robain, M., additional, Couch, D., additional, and Chouaid, C., additional

Published
2021
Full Text
View/download PDF

43. 53P Studying autoimmune diseases with thymic epithelial tumors (TET): Real-world insight from RYTHMIC

Author

Benitez, J.C., primary, Boucher, M-E., additional, Dansin, E., additional, Kerjouan, M., additional, Bigay-Game, I., additional, Pichon, E., additional, Thillays, F., additional, Falcoz, P.E., additional, Lyubimova, S., additional, Oulkhouir, Y., additional, Calcagno, F., additional, Thiberville, L., additional, Clément-Duchêne, C., additional, Morin, F., additional, Missy, P., additional, Thomas, P., additional, Maury, J., additional, Molina, T., additional, Girard, N., additional, and Besse, B., additional

Published
2020
Full Text
View/download PDF

46. 1392P Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)

Author

Descourt, R., primary, Pérol, M., additional, Planchard, D., additional, Rousseau-Bussac, G., additional, Mennecier, B., additional, Wislez, M., additional, Cadranel, J., additional, Cortot, A.B., additional, Guisier, F., additional, Do, P., additional, Schott, R., additional, Dansin, E., additional, Arrondeau, J., additional, Auliac, J.B., additional, Chouaid, C., additional, and Galland, L., additional

Published
2020
Full Text
View/download PDF

47. LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683

Author

Le Pechoux, C., primary, Pourel, N., additional, Barlesi, F., additional, Faivre-Finn, C., additional, Lerouge, D., additional, Zalcman, G., additional, Antoni, D., additional, Lamezec, B., additional, Nestle, U., additional, Boisselier, P., additional, Thillays, F., additional, Paumier, A., additional, Dansin, E., additional, Peignaux, K., additional, Madelaine, J., additional, Pichon, E., additional, Larrouy, A., additional, Riesterer, O., additional, Lavole, A., additional, and Bardet, A., additional

Published
2020
Full Text
View/download PDF

48. 1899P Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET)

Author

Montanez, J.C. Benitez, primary, Boucher, M-É., additional, Dansin, E., additional, Kerjouan, M., additional, Mazieres, J., additional, Pichon, E., additional, Thillays, F., additional, Falcoz, P.E., additional, Roch, B., additional, Oulkhouir, Y., additional, Calcagno, F., additional, Thiberville, L., additional, Clément-Duchêne, C., additional, Morin, F., additional, Missy, P., additional, Thomas, P.A., additional, Maury, J.-M., additional, Molina, T., additional, Girard, N., additional, and Besse, B., additional

Published
2020
Full Text
View/download PDF

50. Rechallenge avec les inhibiteurs des points de contrôle immunitaires (ICPis) : issues cliniques dans une cohorte nationale française de patients atteints d’un cancer bronchique non à petites cellules (CBNPC)

Author

Giaj Levra, M., primary, Gobbini, E., additional, Pérol, M., additional, Assié, J.B., additional, Duruisseaux, M., additional, Coupez, D., additional, Gervais, R., additional, Westeel, V., additional, Delaunay, M., additional, Guisier, F., additional, Veillon, R., additional, Gounant, V., additional, Giroux Leprieur, E., additional, Vanel, F.R., additional, Chaabane, N., additional, Dansin, E., additional, Babey, H., additional, Decroisette, C., additional, Barlesi, F., additional, Catherine, D., additional, Fournel, P., additional, Mezquita, L., additional, Oulkhouir, Y., additional, Canellas, A., additional, Duchemann, B., additional, Molinier, O., additional, Moro-Sibilot, D., additional, and Toffart, A.C., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results